Skip to main content
MedinCell S.A. logo

MedinCell S.A. — Investor Relations & Filings

Ticker · MEDCL ISIN · FR0004065605 LEI · 969500R79U6PXCL2FF46 PA Manufacturing
Open in API
Filings indexed 516 across all filing types
Latest filing 2026-04-29 Earnings Release
Country FR France
Listing PA MEDCL

About MedinCell S.A.

https://www.medincell.com/en/

MedinCell S.A. is a pharmaceutical company at the commercial stage that specializes in the development of long-acting injectable (LAI) therapies. The company's core is its proprietary BEPO® technology platform, which enables the controlled and sustained release of active pharmaceutical ingredients over periods ranging from days to months after a single injection. This technology forms a fully biodegradable depot in situ, designed to improve treatment efficiency, enhance patient compliance, and increase the global accessibility of medicines. MedinCell develops a portfolio of LAI products across various therapeutic areas, including psychiatry, advancing its pipeline through both internal research and strategic partnerships with other pharmaceutical organizations.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a corporate press release dated April 29, 2026, presenting Medincell’s key financial metrics for Q1 2026 (net sales figures, year-on-year growth, royalty details, and future commercial milestones). It provides headline financial results without full financial statements or extensive narrative analysis. This aligns with the definition of an Earnings Release (ER) rather than a comprehensive interim report or annual report. Q1 2026
2026-04-29 French
Inside Information / Other news releases
Earnings Release Classification · 90% confidence The document is a press release titled “Q1 2026 Net Sales Reached $63M,” providing key highlights of the company’s quarterly financial performance (net sales, year‐on‐year growth, milestone payments, and approval updates) without full financial statements. This fits the definition of an initial announcement of quarterly/periodical financial results, classifying it as an Earnings Release (ER). Q1 2026
2026-04-29 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 82% confidence The document is a press release announcing initiation of analyst coverage by Degroof Petercam and a buy recommendation for Medincell’s shares. It does not present financial results, AGM materials, regulatory filings such as a 10-K or interim report, nor is it a dividend notice, capital raising, or share transaction. It is a general corporate press release without a specific specialized category, so it falls into the fallback “Regulatory Filings (RNS)” category.
2026-04-22 French
Inside Information / Other news releases
Regulatory Filings Classification · 56% confidence The document is a corporate press release announcing that an investment bank (Degroof Petercam) has initiated coverage of Medincell with a “Buy” recommendation. It is not a financial earnings release, a report itself, or any other specific filing type. It does not announce board changes, dividends, share issues, or regulatory filings of financial results. Therefore it falls into the general/regulatory announcements fallback category (RNS).
2026-04-22 English
Inside Information / Other news releases
Regulatory Filings Classification · 61% confidence The document is a corporate press release announcing that Leerink Partners has initiated coverage of Medincell with an “Outperform” rating. It does not contain financial results or formal filings (e.g., earnings, annual report, proxy statement) nor does it relate to share issues, management changes, legal matters, or dividends. This type of general corporate announcement falls into the fallback category for miscellaneous regulatory announcements.
2026-04-21 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 45% confidence The document is a press release (“Communiqué de presse”) announcing that Leerink Partners has initiated coverage of Medincell with an Outperform recommendation and price target. It does not present company financial results, dividend notices, management changes, share issues, or detailed report filings—it is neither an earnings release nor a formal investor presentation. It is a general corporate announcement disclosed on the exchange without fitting any more specific category, so it defaults to Regulatory Filings (RNS).
2026-04-21 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.